Comments asbe Mesoblast (MESO) ADRs added ~6% on Friday after the Australian biotech said that gross revenue from its cell therapy Ryoncil reached $35.1M during the December 2025 quarter, indicating a ~60% jump from the preceding quarter. In 2024, the FDA approved Ryoncil Post navigation Aragen Launches CHOMax Cell Line Development and Manufacturing PlatformCG Oncology rises after expediting a late-stage trial readout for lead asset
Comments asbe Mesoblast (MESO) ADRs added ~6% on Friday after the Australian biotech said that gross revenue from its cell therapy Ryoncil reached $35.1M during the December 2025 quarter, indicating a ~60% jump from the preceding quarter. In 2024, the FDA approved Ryoncil
